These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 29853933)
1. A study on OPG/RANK/RANKL axis in osteoporotic bile duct-ligated rats and the involvement of nitrergic and opioidergic systems. Doustimotlagh AH; Dehpour AR; Etemad-Moghadam S; Alaeddini M; Ostadhadi S; Golestani A Res Pharm Sci; 2018 Jun; 13(3):239-249. PubMed ID: 29853933 [TBL] [Abstract][Full Text] [Related]
2. Nitrergic and opioidergic systems affect radiographic density and histomorphometric indices in bile-duct-ligated cirrhotic rats. Doustimotlagh AH; Dehpour AR; Etemad-Moghadam S; Alaeddini M; Kheirandish Y; Golestani A Histol Histopathol; 2017 Jul; 32(7):743-749. PubMed ID: 27782295 [TBL] [Abstract][Full Text] [Related]
3. [Electroacupuncture Intervention Improves Cartilage Degeneration and Subchondral Bone Osteoporosis of Knee-joint Possibly by Adjusting OPG/RANK/RANKL Signaling in Ovariectomized Rats]. Sun GH; Liao Y; Liao Y; Ni ZY; Li N; Zhong PR; Li XH; Zhou J Zhen Ci Yan Jiu; 2018 Dec; 43(12):781-7. PubMed ID: 30585456 [TBL] [Abstract][Full Text] [Related]
4. Cirrhosis induced by bile duct ligation alleviates acetic acid intestinal damages in rats: Involvements of nitrergic and opioidergic systems. Rahimi N; Hassanipour M; Allahabadi NS; Sabbaghziarani F; Yazdanparast M; Dehpour A Pharmacol Rep; 2018 Jun; 70(3):426-433. PubMed ID: 29626646 [TBL] [Abstract][Full Text] [Related]
5. Nitric oxide mediates the beneficial effect of chronic naltrexone on cholestasis-induced memory impairment in male rats. Javadi-Paydar M; Ghiassy B; Ebadian S; Rahimi N; Norouzi A; Dehpour AR Behav Pharmacol; 2013 Jun; 24(3):195-206. PubMed ID: 23591123 [TBL] [Abstract][Full Text] [Related]
6. The influence of TRAIL, adiponectin and sclerostin alterations on bone loss in BDL-induced cirrhotic rats and the effect of opioid system blockade. Moradi M; Doustimotlagh AH; Dehpour AR; Rahimi N; Golestani A Life Sci; 2019 Sep; 233():116706. PubMed ID: 31369758 [TBL] [Abstract][Full Text] [Related]
7. Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones. Ikeda T; Utsuyama M; Hirokawa K J Bone Miner Res; 2001 Aug; 16(8):1416-25. PubMed ID: 11499864 [TBL] [Abstract][Full Text] [Related]
8. Osteoprotegerin/RANK/RANKL axis in cardiac remodeling due to immuno-inflammatory myocardial disease. Liu W; Feng W; Wang F; Li W; Gao C; Zhou B; Ma M Exp Mol Pathol; 2008 Jun; 84(3):213-7. PubMed ID: 18417124 [TBL] [Abstract][Full Text] [Related]
9. Resistance of cholestatic rats against epinephrine-induced arrhythmia: the role of nitric oxide and endogenous opioids. Hajrasouliha AR; Tavakoli S; Jabehdar-Maralani P; Shafaroodi H; Borhani AA; Houshmand G; Sadeghipour H; Dehghani M; Dehpour AR Eur J Pharmacol; 2004 Sep; 499(3):307-13. PubMed ID: 15381053 [TBL] [Abstract][Full Text] [Related]
10. Zinc supplements and bone health: The role of the RANKL-RANK axis as a therapeutic target. Amin N; Clark CCT; Taghizadeh M; Djafarnejad S J Trace Elem Med Biol; 2020 Jan; 57():126417. PubMed ID: 31653549 [TBL] [Abstract][Full Text] [Related]
11. The osteoprotegerin/receptor activator of nuclear factor kappaB/receptor activator of nuclear factor kappaB ligand system in cartilage. Komuro H; Olee T; Kühn K; Quach J; Brinson DC; Shikhman A; Valbracht J; Creighton-Achermann L; Lotz M Arthritis Rheum; 2001 Dec; 44(12):2768-76. PubMed ID: 11762937 [TBL] [Abstract][Full Text] [Related]
12. Effects of relaxin and estrogens on bone remodeling markers, receptor activator of NF-kB ligand (RANKL) and osteoprotegerin (OPG), in rat adjuvant-induced arthritis. Ho TY; Santora K; Chen JC; Frankshun AL; Bagnell CA Bone; 2011 Jun; 48(6):1346-53. PubMed ID: 21419242 [TBL] [Abstract][Full Text] [Related]
13. Exploring the impact of naltrexone on the THBS1/eNOS/NO pathway in osteoporotic bile duct-ligated rats. Hosseini-Fard SR; Etemad-Moghadam S; Alaeddini M; Dehpour AR; Emamgholipour S; Golestani A Sci Rep; 2024 Jan; 14(1):48. PubMed ID: 38167957 [TBL] [Abstract][Full Text] [Related]
14. Expression and Distribution of Receptor Activator of Nuclear Factor Kappa B, Receptor Activator of Nuclear Factor Kappa B Ligand, and Osteoprotegerin in Periradicular Cysts. Armada L; Marotta Pdos S; Pires FR; Siqueira JF J Endod; 2015 Aug; 41(8):1281-7. PubMed ID: 25956608 [TBL] [Abstract][Full Text] [Related]
15. Potential role of the OPG/RANK/RANKL axis in prostate cancer invasion and bone metastasis. Li X; Liu Y; Wu B; Dong Z; Wang Y; Lu J; Shi P; Bai W; Wang Z Oncol Rep; 2014 Dec; 32(6):2605-11. PubMed ID: 25333856 [TBL] [Abstract][Full Text] [Related]
16. Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism. Stilgren LS; Rettmer E; Eriksen EF; Hegedüs L; Beck-Nielsen H; Abrahamsen B Bone; 2004 Jul; 35(1):256-65. PubMed ID: 15207766 [TBL] [Abstract][Full Text] [Related]
17. Nitric oxide regulates receptor activator of nuclear factor-kappaB ligand and osteoprotegerin expression in bone marrow stromal cells. Fan X; Roy E; Zhu L; Murphy TC; Ackert-Bicknell C; Hart CM; Rosen C; Nanes MS; Rubin J Endocrinology; 2004 Feb; 145(2):751-9. PubMed ID: 14563699 [TBL] [Abstract][Full Text] [Related]
18. Effect of Zuoguiwan on osteoporosis in ovariectomized rats through RANKL/OPG pathway mediated by β2AR. Liu F; Tan F; Tong W; Fan Q; Ye S; Lu S; Teng Z; Han M; Zhang M; Chai Y Biomed Pharmacother; 2018 Jul; 103():1052-1060. PubMed ID: 29710663 [TBL] [Abstract][Full Text] [Related]
19. RANK/RANKL/OPG system in the intervertebral disc. Takegami N; Akeda K; Yamada J; Sano T; Murata K; Huang J; Masuda K; Sudo A Arthritis Res Ther; 2017 Jun; 19(1):121. PubMed ID: 28576140 [TBL] [Abstract][Full Text] [Related]
20. Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin. Li X; Ominsky MS; Stolina M; Warmington KS; Geng Z; Niu QT; Asuncion FJ; Tan HL; Grisanti M; Dwyer D; Adamu S; Ke HZ; Simonet WS; Kostenuik PJ Bone; 2009 Oct; 45(4):669-76. PubMed ID: 19539794 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]